Phase 1/2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 01 Sep 2016
At a glance
- Drugs Marizomib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Nereus Pharmaceuticals; Triphase Accelerator Corporation
- 23 Mar 2016 Results (n=68) from the phase I part of the study published in the Blood.
- 22 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 Mar 2014 Planned End Date changed from 1 Dec 2014 to 1 Sep 2015 as reported by ClinicalTrials.gov record.